GSEP
ABBV icon

Golden State Equity Partners’s AbbVie ABBV Stock Holding History

Golden State Equity Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8M Buy
36,793
+16,953
+85% +$3.76M 0.61% 26
2025
Q4 		$4.53M Buy
19,840
+2,735
+16% +$623K 0.73% 20
2025
Q3 		$3.96M Sell
17,105
-3,143
-16% -$640K 0.67% 27
2025
Q2 		$3.76M Buy
20,248
+57
+0.3% +$10.6K 0.7% 25
2025
Q1 		$4.23M Sell
20,191
-363
-2% -$70.6K 0.84% 18
2024
Q4 		$3.65M Buy
20,554
+14,780
+256% +$2.72M 0.7% 26
2024
Q3 		$1.14M Sell
5,774
-10,804
-65% -$2.02M 0.6% 28
2024
Q2 		$2.84M Buy
+16,578
New +$2.75M 0.59% 33
2023
Q4 		$2.57M Sell
16,573
-254
-2% -$37K 0.62% 36
2023
Q3 		$2.51M Sell
16,827
-182
-1% -$26.7K 0.7% 34
2023
Q2 		$2.29M Buy
17,009
+5,617
+49% +$824K 0.64% 32
2023
Q1 		$1.82M Buy
+11,392
New +$1.74M 0.98% 29
2022
Q1 		$1.11M Buy
6,864
+1,024
+18% +$149K 0.56% 54
2021
Q4 		$791K Sell
5,840
-3,809
-39% -$450K 0.4% 62
2021
Q3 		$1.04M Buy
9,649
+4,549
+89% +$520K 0.42% 58
2021
Q2 		$574K Buy
+5,100
New +$574K 0.22% 112

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Golden State Equity Partners's ABBV Position: Q1 2026 in Review

Golden State Equity Partners increased its AbbVie (ABBV) stake by 85% in Q1 2026, buying an estimated $3.76M and bringing the position to 36,793 shares worth $8M. The position accounts for 0.61% of the portfolio, ranked #26.

Golden State Equity Partners first reported a position in ABBV in Q2 2021 and has held it in 16 quarters since. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Golden State Equity Partners held 36,793 shares of AbbVie worth $8M as of Q1 2026.
  • Golden State Equity Partners bought 16,953 AbbVie shares in Q1 2026, an estimated $3.76M.
  • AbbVie made up 0.61% of Golden State Equity Partners's portfolio in Q1 2026, its #26 holding.
  • Golden State Equity Partners first reported a position in AbbVie in Q2 2021 and has held it in 16 quarters since.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.